Every rule your marketing answers to.

Warrant reviews your marketing against 3,388 rules from 1,267 regulators across 11 countries. Every flag is cited to its source. Search the full library below.

Coverage includes the FTC, FDA, CFPB, SEC, FINRA, NCUA, FDIC, OCC, NAIC, and regulators from all 50 U.S. states, the European Union, Canada, and more.

Get a free homepage compliance scan

Regulation guides

21 CFR 101 - Food Labeling

FDA's food labeling rules require a Nutrition Facts panel and other label elements and restrict nutrient and 'healthy' claims to foods meeting FDA criteria; the amended 'healthy' definition is effective April 28, 2025 with compliance required by Feb. 25, 2028.

21 CFR Part 101; 21 CFR 101.65(d) (amended Dec. 27, 2024)

21 CFR 201 - Drug Labeling

21 CFR Part 201 requires OTC drug labels to carry a standardized Drug Facts panel and prescription labels to carry 'Rx only', with label claims consistent with approved labeling.

21 CFR Part 201 (incl. 201.66, 201.100); 21 U.S.C. 353(b)(4)

FDA Anticaries Drug Products

Limits fluoride toothpaste and rinse labels to the OTC anticaries monograph indication and requires a complete Drug Facts panel.

21 U.S.C. 355h; OTC Monograph M021.1, M021.50(b), (c)(1)-(2), (d)(1)-(5); 21 CFR 201.66(c)(1)-(6), (c)(5)(x)

FDA Anticaries Monograph Compliance

Limits ads for fluoride anticavity products to the monograph's cavity-prevention claim and bars overstated or unsupported drug benefits.

21 U.S.C. 355h; 21 CFR 355.50(b) (OTC Monograph M021); FTC Act Secs. 5 and 12, 15 U.S.C. 45(a)(1), 52

FDA Antidandruff Monograph Compliance

Limits dandruff, seborrheic dermatitis and psoriasis claims to those the OTC monograph permits for the product's active ingredient, and bars cure or permanence claims.

21 U.S.C. 355h(a)(1); OTC Monograph M032 (former 21 CFR 358 Subpart H)

FDA Antiperspirant Monograph Compliance

Limits antiperspirant claims to monograph-permitted wetness claims, bars sweat claims for deodorants without an active, and requires the kidney-disease warning on labels.

21 U.S.C. 355h(a)(1); OTC Monograph M019 (former 21 CFR 350.50)

FDA Beverage Standards

Requires beverage names to match juice content and bottled-water identity standards, a percent-juice statement on juice beverage labels, and 'healthy' only where FDA criteria are met.

21 U.S.C. 343; 21 CFR 101.30, 102.33(a), 101.65(d)(3), 165.110(a)(2)

FDA Cosmetic Labeling Requirements

Requires cosmetic labels to show identity, net quantity, ingredients, the responsible firm's name and place of business, and applicable warnings.

21 U.S.C. 362(b); 21 CFR 701.3, 701.11, 701.12, 701.13, 740.11

FDA Cosmetic Labeling Standards

Cosmetic labels must show identity, net quantity, an ingredient declaration in descending order, the responsible business's name and place, a MoCRA adverse-event contact, and required warnings.

21 CFR 701.3, 701.11, 701.12, 701.13; 21 CFR 740; FD&C Act 602, 609(a) (MoCRA)

FDA Cosmetics Advertising & Labeling (MoCRA)

Requires MoCRA's adverse-event contact information and professional-use statements on cosmetic labels and bars claims that a cosmetic is FDA approved.

21 U.S.C. 362, 364e (FD&C 602, 609)

FDA Cosmetics General Regulations

Cosmetics may not contain prohibited or restricted ingredients or unlisted colors, must carry 21 CFR 740 warnings where required, and may not make drug claims.

21 CFR 700.11-700.35; 21 CFR 73, 74, 82; 21 CFR 740; FD&C Act 201(i), 601, 602

FDA Dietary Supplement Advertising & Labeling (DSHEA)

Bars supplement disease claims and requires the DSHEA disclaimer with structure/function claims in labeling and a Supplement Facts panel on labels.

21 U.S.C. 343(r)(6); 21 CFR 101.93(c), (d), (g)(2)(i); 21 CFR 101.36(a), (b), (e)

FDA Dietary Supplement Claims

Bars supplement marketing that implies a disease effect through product names, images, testimonials, cited publications or disease symptoms.

21 U.S.C. 343(r)(6); 21 CFR 101.93(g)(2)(i), (ii), (iv)(A), (C), (E), (x)

FDA Dietary Supplement Health Claims

Bars supplement marketing that positions the product as a substitute for, enhancer of or equivalent to a drug or medical treatment.

21 U.S.C. 343(r)(6); 21 CFR 101.93(g)(2)(iv)(B), (vi), (vii), (x); 15 U.S.C. 45, 52

FDA Direct-to-Consumer (DTC) Prescription Drug Advertising

Requires consumer TV, radio and video prescription drug ads to present the major statement of risks clearly, conspicuously and neutrally and to provide a brief summary or adequate provision.

21 CFR 202.1(e)(1) (as amended, 88 FR 80958, compliance Nov. 20, 2024)

FDA Direct-to-Consumer Prescription Drug Ads

Requires DTC Rx ads to present the major risk statement clearly, conspicuously and neutrally, to provide adequate provision for full prescribing information in broadcast, and to include a brief summary in print.

21 U.S.C. 352(n); 21 CFR 202.1(e)(1), (e)(6)

FDA Drug Definition Standards

Supplements, cosmetics, foods and CBD products become unapproved drugs if their marketing claims to diagnose, treat, cure, mitigate or prevent disease, and cosmetics also may not claim to affect body structure or function.

21 U.S.C. 321(g)(1), 321(i), 343(r)(6); 21 CFR 101.93(g)(2)

FDA Drug Labeling Requirements

Requires OTC drug labels to carry a complete Drug Facts panel in the prescribed order and format with ingredient-specific warnings.

21 CFR 201.66; 21 U.S.C. 352

FDA External Drug Products

OTC external drug products covered by 21 CFR 358 (warts, corns and calluses, ingrown toenails, lice, dandruff, seborrheic dermatitis, psoriasis) may only claim the uses and actives in their monograph.

21 CFR 358 (deemed final OTC monograph orders, FD&C Act 505G)

FDA False or Misleading Medical Device Claims

Device promotion must not make false, absolute or unsubstantiated performance, safety or superiority claims; quantified and comparative claims need a cited basis.

21 U.S.C. 352(a)(1), 352(q)(1); 15 U.S.C. 45, 52; FTC Advertising Substantiation Policy Statement

FDA Food Additive Regulations

FDA food additive rules require additives to be approved or GRAS, and labeling rules require certified colors and preservatives to be declared properly; 'no artificial' or 'no preservative' claims must match the ingredient list.

21 U.S.C. 343(a)(1), 343(k); 21 CFR 101.22(j), (k)(1); 21 CFR 170.30; 89 FR 55040 (BVO revocation)

FDA Food Labeling - 'Natural' Claims

Under FDA's longstanding informal policy, 'natural' on food means nothing artificial or synthetic, including any added color, has been added that would not normally be expected; misleading 'natural' claims misbrand food.

21 U.S.C. 343(a)(1); 21 CFR 101.22(i); FDA 'natural' policy (58 FR 2302)

FDA Food Labeling - Health Claims (21 CFR 101.14)

Food and supplement labels may link a substance to reduced disease risk only through FDA-authorized or qualified health claims, in the required form, and only on foods meeting nutrient eligibility; disease treatment claims are not allowed.

21 CFR 101.14; 21 CFR 101.72-101.83; 21 U.S.C. 343(r)

FDA Food Labeling - Nutrient Content Claims (21 CFR 101.13)

Nutrient content claims such as 'low fat', 'sugar free', 'light' and 'healthy' may be used only when the food meets FDA's defined per-serving criteria, with reference statements on comparative claims and a disclosure statement when disqualifying nutrient levels are exceeded.

21 CFR 101.13; 21 CFR 101.54-101.69

FDA Food Labeling Requirements

Packaged food labels must carry identity, net contents, ingredients, a major-allergen declaration (nine allergens including sesame), the responsible firm's name and address, and Nutrition Facts unless exempt.

21 U.S.C. 343(e), (i), (q), (w); 21 CFR 101.3(a), 101.4(a)(1), 101.5(a), 101.9(a), 101.105(a)

FDA Food Standards of Identity

A food sold under a name defined by an FDA standard of identity must meet that standard; non-conforming products must use a different or qualified name, or 'imitation' when nutritionally inferior.

21 U.S.C. 343(g); 21 CFR Parts 130-169

FDA Gluten-Free Labeling Requirements

Foods may say 'gluten-free' only if they contain no gluten-containing grain or unprocessed derivative and have less than 20 ppm gluten.

21 CFR 101.91

FDA Healthcare Social Media Marketing

Social media promotion that names a prescription drug or restricted device and makes a benefit claim must present the most serious risks in the same post with balanced prominence and a link to full risk information.

21 U.S.C. 352(a), (n); 21 CFR 202.1(e); FDA Character Space Draft Guidance (2014)

FDA Homeopathic Drug Products

Homeopathic products are drugs; marketing must not imply FDA approval, must not promote them for serious diseases, and efficacy claims must be scientifically supported or clearly qualified as based only on homeopathic theory.

21 U.S.C. 321(g)(1), 352; FDA Guidance: Homeopathic Drug Products (Dec 2022); FTC Enforcement Policy Statement on OTC Homeopathic Drug Claims (2016)

FDA Infant Formula & Baby Food Advertising

Infant formula and baby food marketing must not be misleading, including claims of equivalence to breast milk, disease prevention, guaranteed development or absolute contaminant-free status; formulas must meet FDA nutrient and notification requirements.

21 U.S.C. 343(a)(1), 343(r), 350a; 15 U.S.C. 45, 52

FDA Medical Device Advertising and Promotion

Device promotion must describe FDA status accurately (cleared, approved or De Novo authorized), must not imply approval from registration, must not promote investigational devices, and restricted-device ads need a brief risk statement.

21 U.S.C. 352(a), (q), (r); 21 CFR 807.39, 807.97, 812.7

FDA MoCRA Cosmetics Modernization — Marketing Claims

Cosmetic marketing must stay within cosmetic (appearance) claims, must not imply FDA approval, and cosmetic labels must include MoCRA adverse-event contact information.

21 U.S.C. 321(g)(1), 321(i), 362, 364e(a); 7 CFR 205.304(c), 205.311(a)

FDA MoCRA Cosmetics Registration Requirements

Under MoCRA, cosmetic labels must give a US address, US phone number or electronic contact for adverse-event reports, and professional-use products must say they are for licensed professionals only.

21 U.S.C. 364e (FD&C 609)

FDA Non-Compliant Medical Software Marketing

Health software marketing must not claim FDA status it lacks, make diagnostic or disease claims for wellness or excluded software, or claim to replace clinicians.

21 U.S.C. 321(h), 352(a), 360j(o)(1)

FDA Non-Compliant Prescription Drug Advertising

Rx drug ads must present risks with fair balance, include a brief summary or major statement, keep broadcast risk statements clear, conspicuous and neutral, stay within the label, and compounded-drug ads must not imply FDA approval or brand equivalence.

21 U.S.C. 352(a), (n), (bb); 21 CFR 202.1(e)(1), (e)(5), (e)(6), (e)(7)

FDA Nutrition Labeling Requirements

Food labels must use the current Nutrition Facts format with RACC-based servings, and nutrient content and 'healthy' claims must meet FDA definitions and be consistent with the label.

21 U.S.C. 343(q), 343(r); 21 CFR 101.9(b)(6), (b)(12), (c)(6)(iii), (c)(8)(ii), (d)(1); 101.13(h)(1); 101.65(d)

FDA OTC Drug Labeling Requirements

OTC drug labels must carry a Drug Facts panel in the 21 CFR 201.66 format with the ingredient-specific warnings, such as the acetaminophen liver warning and aspirin Reye's syndrome warning.

21 CFR 201.66; 21 CFR 201.63, 201.314(h), 201.326

FDA OTC Drug Monograph System (Sunscreens, Acne, Antiperspirants)

Limits OTC monograph drug claims (sunscreens, acne, antiperspirants) to permitted indications and terms, bans terms such as 'sunblock' and 'waterproof', and requires Drug Facts on labeling.

21 U.S.C. 355h; 21 CFR 201.66, 201.327; former 21 CFR 333.310, 333.350, 350.50

FDA Off-Label Promotion - Digital and HCP Communication Risks

Firm communications sharing scientific information on unapproved uses with HCPs must follow FDA's January 2025 final SIUU guidance: scientifically sound sources, required disclosures, no persuasive elements, and separation from promotion.

21 U.S.C. 352(a), (f); 21 CFR 202.1; FDA SIUU Q&A Guidance (Jan. 2025)

FDA Off-Label Promotion - Prohibited Practices and Safe Harbors

Prescription drug promotion must stay within the approved indication; information on unapproved uses may be shared only separately from promotion under FDA's safe-harbor guidance or in reply to unsolicited requests.

21 U.S.C. 331(a), 352(a)(1), 352(f); 21 CFR 201.128; 21 CFR 202.1(e)(6)(i), (xi)

FDA Off-Label Promotion of GLP-1 Weight Loss (Ozempic, Wegovy)

GLP-1 ads must not promote diabetes-only brands for weight loss, imply compounded products are FDA-approved or equivalent to brands, guarantee results, or omit risk information for branded drugs.

21 U.S.C. 352(a), (n), (bb), 353a, 353b; 21 CFR 202.1(e)

FDA Prescription Drug Advertising (21 CFR 202)

Requires prescription drug advertising in all channels to present risks with fair balance, include a brief summary or equivalent, and avoid overstated, off-label or unsupported claims.

21 CFR 202.1(e); FD&C Act § 502(n)

FDA SaMD Marketing

SaMD marketing must use the correct FDA status term (approved only for PMA devices, cleared for 510(k)), must not imply FDA endorsement or treat registration as approval, and must not claim uses beyond the authorized intended use.

21 U.S.C. 352(a), (o); 21 CFR 801.4, 807.39, 807.97

FDA Sexual Wellness Medical Device Requirements

Sexual wellness products that make therapeutic, contraceptive or STI-prevention claims are regulated as medical devices and may make those claims only within an FDA clearance or approval.

21 U.S.C. 321(h)(1), 352(a)(1), 352(o); 21 CFR 807.39, 807.97, 884.5300

FDA Social Media Prescription Drug Rules

Rx drug posts by brands and paid creators must include the drug names, indication, the most serious risks and a link to full risk information, and sponsored posts need a clear material-connection disclosure under FTC rules.

21 U.S.C. 352(a), (n); 21 CFR 202.1; 16 CFR 255.5; FDA Character Space Draft Guidance (2014)

FDA Sports Nutrition DSHEA Compliance

Sports supplements may make structure/function claims only with the full FDA disclaimer on labeling and must not make disease or drug-equivalent claims.

21 U.S.C. 321(g)(1), 343(r)(6); 21 CFR 101.93(c), (d), (g)(2)

FDA Sunscreen Labeling Requirements

US OTC sunscreen labels and promotional copy must use monograph-permitted SPF, broad spectrum and water resistance statements, Drug Facts and required warnings, and avoid prohibited terms like sunblock and waterproof.

21 CFR 201.327, 201.66; 21 U.S.C. 355h

FDA Sunscreen Monograph Compliance

Sunscreen marketing must use monograph-consistent claims: no 'sunblock', 'waterproof', 'sweatproof', instant or all-day protection claims, water resistance only as 40 or 80 minutes, and broad-spectrum and skin-cancer claims only for qualifying products.

21 CFR 201.327; OTC Monograph M020

FDA Sunscreen OTC Drug Standards

OTC sunscreens may use only monograph-listed active ingredients within permitted concentrations, and labels must carry a complete Drug Facts panel and, where required, the Skin Cancer/Skin Aging Alert.

21 CFR 201.66; 21 CFR 201.327; OTC Monograph M020

FDA Supplement GMPs and New Dietary Ingredients

Supplement marketing may describe cGMP manufacturing accurately but may not claim FDA approval or certification of the product or facility, which FDA does not give.

21 CFR 111; FD&C Act 413 (21 U.S.C. 350b); FD&C Act 403(a); FTC Act 5, 12

FDA Supplement Third-Party Testing Claims

Testing, purity and certification-seal claims for supplements, CBD and OTC products must be truthful and match what was actually tested or certified.

15 U.S.C. 45, 52, 1125(a); FTC Health Products Compliance Guidance (2022)

FDA Telehealth & Online Pharmacy Advertising

Telehealth and online pharmacy ads must not claim or imply that compounded drugs are FDA-approved, generic or equivalent to branded drugs, or proven safe and effective, and ads making drug benefit claims must include risk information.

21 U.S.C. 352(a), (n), (bb), 353(b)(1); 21 CFR 202.1; 15 U.S.C. 45, 52

FDA Unauthorized Medical Device Off-Label Promotion

Medical device promotion must stay within the cleared or approved indications; promoting other uses is misbranding, and restricted-device ads need a brief statement of intended uses and risks.

21 U.S.C. 352(a), (o), (q), (r); 21 CFR 801.4

FDA Weight Loss Product Labeling and Safety Standards

Weight-loss product marketing must avoid unrealistic or drug-equivalent claims and banned ingredients, disclose typical results for testimonials, and carry Supplement Facts and the DSHEA disclaimer on labeling.

21 U.S.C. 342(f)(1)(A), 343(a)(1), 343(r)(6); 21 CFR 101.36(a), (e)(1); 21 CFR 101.93(c), (d), (f), (g)(2); 21 CFR 119.1; 15 U.S.C. 45(a)(1), 52(a)-(b); 16 CFR 255.2(a)-(b)

FDCA Section 403

FDCA Section 403 deems food misbranded if its labeling is false or misleading or lacks required elements such as the statement of identity, net quantity, ingredients, major allergens, manufacturer details and nutrition labeling.

21 U.S.C. 343(a), (e), (g), (i), (w); 21 CFR 101.3, 101.4, 101.5, 101.22(i), 101.30, 101.105

Food Allergen Labeling (FALCPA)

Under FALCPA as amended by the FASTER Act, packaged food labels must name the source of each of the nine major food allergens in the ingredient list or a complete 'Contains' statement.

21 U.S.C. 343(w)(1)(A)-(B), (w)(2); 21 U.S.C. 321(qq)(1) as amended by the FASTER Act of 2021

Food Standards of Identity

Standardized food names may be used only for products meeting FDA standards of identity; nutritionally inferior substitutes must be labeled 'imitation', while qualified plant-based names are generally allowed.

21 U.S.C. 343(c), 343(g); 21 CFR Parts 130-169; 21 CFR 101.3(e)

Nutrient Content Claims

'Healthy' as an implied nutrient content claim requires a minimum food-group contribution and limits on added sugars, saturated fat and sodium under the updated 21 CFR 101.65(d); old criteria may be used until Feb. 25, 2028.

21 U.S.C. 343(r); 21 CFR 101.65(d)

Browse by category

Browse by jurisdiction

Browse by regulator